Ketamine inhibits endometrial cancer cell growth and motility by inducing ferroptosis

Endometrial cancer (EC) is a prevalent gynecological malignancy with an escalating incidence and mortality rate, notably in China. Surgical options are limited, and drug resistance development poses significant challenges to EC treatment. Ketamine, a rapid-acting anesthetic, exhibits anti-inflammatory, analgesic, and antidepressant properties, yet its potential in cancer therapy remains largely unexplored. Here, we investigate ketamine’s effects on EC cell growth, motility and ferroptosis, alongside its impact on the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/the mammalian target of rapamycin (mTOR) axis. Ketamine significantly inhibits EC cell growth and motility while promoting ferroptosis. Mechanistically, ketamine’s anti-tumor effects correlate with suppression of the PI3K/Akt/mTOR axis crucial for cell survival and growth. In summary, our findings highlight ketamine’s potential therapeutic application in EC treatment by impeding cell growth and motility, fostering ferroptosis, and suppressing the PI3K/Akt/mTOR axis. These insights offer novel avenues for EC therapy.

Ketamine; Endometrial cancer; Ferroptosis; PI3K/Akt/mTOR; Cell growth; Cell motility

[1] Tubridy EA, Taunk NK, Ko EM. Treatment of node-positive endometrial cancer: chemotherapy, radiation, immunotherapy, and targeted therapy. Current Treatment Options in Oncology. 2024; 25: 330–345.

[2] Medina-Gutiérrez E, Céspedes MV, Gallardo A, Rioja-Blanco E, Pavón MÀ, Asensio-Puig L, et al. Novel endometrial cancer models using sensitive metastasis tracing for CXCR4-targeted therapy in advanced disease. Biomedicines. 2022; 10: 1680.

[3] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022; 399: 1412–1428.

[4] Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacological Reviews. 2018; 70: 621–660.

[5] Johnston JN, Kadriu B, Kraus C, Henter ID, Zarate CA Jr. Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacology. 2024; 49: 23–40.

[6] Hess EM, Riggs LM, Michaelides M, Gould TD. Mechanisms of ketamine and its metabolites as antidepressants. Biochemical Pharmacology. 2022; 197: 114892.

[7] He GN, Bao NR, Wang S, Xi M, Zhang TH, Chen FS. Ketamine induces ferroptosis of liver cancer cells by targeting lncRNA PVT1/miR-214-3p/GPX4. Drug Design, Development and Therapy. 2021; 15: 3965–3978.

[8] Zhao S, Shao L, Wang Y, Meng Q, Yu J. Ketamine exhibits anti-gastric cancer activity via induction of apoptosis and attenuation of PI3K/Akt/mTOR. Archives of Medical Science. 2020; 16: 1140–1149.

[9] Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between PI3K/Akt signalling pathway and cancer. Gene. 2019; 698: 120–128.

[10] Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in Cancer. Frontiers in Oncology. 2014; 4: 64.

[11] Lu KH, Broaddus RR. Endometrial cancer. New England Journal of Medicine. 2020; 383: 2053–2064.

[12] Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, et al. Endometrial cancer. Nature Reviews Disease Primers. 2021; 7: 88.

[13] Cosialls E, El Hage R, Dos Santos L, Gong C, Mehrpour M, Hamai A. Ferroptosis: cancer stem cells rely on iron until “to die for” it. Cells. 2021; 10: 2981.

[14] Zhang M, Lyu D, Wang F, Shi S, Wang M, Yang W, et al. Ketamine may exert rapid antidepressant effects through modulation of neuroplasticity, autophagy, and ferroptosis in the habenular nucleus. Neuroscience. 2022; 506: 29–37.

[15] Li H, Liu W, Zhang X, Wu F, Sun D, Wang Z. Ketamine suppresses proliferation and induces ferroptosis and apoptosis of breast cancer cells by targeting KAT5/GPX4 axis. Biochemical and Biophysical Research Communications. 2021; 585: 111–116.

[16] Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Seminars in Cancer Biology. 2019; 59: 125–132.

[17] Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L. PI3K/Akt/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database of Systematic Reviews. 2019; 10: CD012160.

[18] Slomovitz BM, Coleman RL. The PI3K/Akt/mTOR pathway as a therapeutic target in endometrial cancer. Clinical Cancer Research. 2012; 18: 5856–5864.